Phase 2 Evidence and Impact Analysis
Article 1 — Mendell et al., EMBARK 3-Year DMD Gene Therapy (PMID: 42944976)
Delandistrogene Moxeparvovec, Phase III EMBARK, 3-Year Follow-Up | DMD | n=64
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Three-year Phase III follow-up data for an AAV-based micro-dystrophin gene therapy is genuinely new; durable transgene expression data are sparse in the field |
| Clinical Relevance | 9 | DMD is uniformly progressive and fatal in early adulthood; gene therapy addressing root cause is the most clinically significant intervention class possible |
| Population Reach | 6 | DMD affects |
| Implementation Speed | 5 | Already FDA-approved (June 2023); label restricted to ages 4–5 with ambulatory criteria; broader use requires label expansion and cost negotiations |
| Evidence Strength | 7 | Phase III RCT design is strong; n=64 is small but acceptable for this ultra-rare disease; 3-year durability is a meaningful signal; abstract-only access limits full appraisal |
Key quantitative result: Sustained micro-dystrophin expression at 3 years (specific functional endpoint data not available from abstract alone). External validation: FDA approval precedes this publication; this is the longest Phase III follow-up reported to date. Main limitation: Small n=64; open-label extension design (not placebo-controlled at 3 years); abstract-only access limits assessment of functional outcome measures (e.g., NSAA scores, 10MWT). Equity implications: Drug cost (~$3.2M/dose) severely limits access globally and even in high-income countries without robust coverage; predominantly benefits ambulatory boys aged 4–5 at treatment; adult DMD patients remain unserved. Evidence Maturity (revised): Validated — Phase III RCT with regulatory approval; 3-year durability data elevates this beyond exploratory. OpenClaw classification as "Exploratory" is underscored; I revise to Validated.
Article 2 — Xue et al., Lianhua Qingwen vs. Oseltamivir in Children (PMID: 42947434)
Multicenter RCT, Pediatric Influenza, LHQW vs. Oseltamivir
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Non-inferiority comparison of a TCM formulation vs. oseltamivir; concept is not new, but rigorous pediatric multicenter RCT data are meaningful additions |
| Clinical Relevance | 6 | Influenza in children is highly prevalent; offering a non-inferior herbal alternative with faster defervescence has practical clinical value, especially where oseltamivir supply/access is limited |
| Population Reach | 7 | Pediatric influenza affects hundreds of millions globally annually; LHQW is widely used in East Asia |
| Implementation Speed | 7 | LHQW already in widespread use in China; regulatory pathway in other jurisdictions would be required for broader adoption |
| Evidence Strength | 7 | Multicenter, double-blind, positive parallel-controlled RCT is a strong design; non-inferiority framework is appropriate; sample size not reported in abstract, limiting full appraisal |
Key quantitative result: LHQW non-inferior to oseltamivir on clinical recovery time; superior defervescence and cough/sore throat improvement. External validation: Prior smaller TCM-influenza studies exist; this is one of the more rigorously designed pediatric RCTs. Main limitation: Sample size unknown from abstract; applicability outside China uncertain (regulatory, supply chain, unfamiliarity); active comparator is oseltamivir, not placebo — robust but scope limited. Equity implications: Could expand affordable treatment options in lower-resource settings where oseltamivir access is limited; however, regulatory barriers outside China are substantial; standardization and quality control of herbal preparations are equity challenges. Evidence Maturity (confirmed): Validated
Article 3 — Li et al., Clinical-Radiological Model for AECOPD Mortality (PMID: 42944679)
Validation Study, Acute Exacerbation COPD In-Hospital Mortality Prediction
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Predictive models for AECOPD mortality are not novel; integrating radiological features with clinical parameters is somewhat incremental |
| Clinical Relevance | 6 | AECOPD carries high in-hospital mortality; outperforming established scores (e.g., BAP-65, CURB) with an AUC of 0.852 in the test set has genuine triage value |
| Population Reach | 7 | COPD affects ~380 million people globally; AECOPD is a leading cause of hospitalization worldwide |
| Implementation Speed | 5 | Logistic regression model is simple and could integrate into EHR systems; external validation in diverse populations needed before clinical deployment |
| Evidence Strength | 6 | Validation study design is appropriate; AUC 0.852 (95% CI 0.738–0.965) is promising but wide CI suggests uncertainty; sample size not reported; single-center or limited-center origin unclear from abstract |
Key quantitative result: AUC 0.852 (95% CI 0.738–0.965) in testing set, outperforming existing clinical scores. External validation: Study described as "validation study" but external generalizability unclear from abstract; wide CI is a caution flag. Main limitation: Sample size not reported; radiological component requires imaging, which may not be available uniformly; wide confidence interval; unknown comparator scores and patient populations. Equity implications: If imaging-reliant, under-resourced settings may not benefit; a simpler clinical-only model offshoot could widen access. Evidence Maturity (confirmed): Validated (internal validation demonstrated, external replication still needed)
Article 4 — Fujii et al., GLP-1 RA Cardiovascular Effects by Age Group Meta-Analysis (PMID: 42946897)
Systematic Review and Meta-Analysis, GLP-1 RA CVD Outcomes by Age
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Age-stratified CV outcomes meta-analysis for GLP-1 RAs fills a specific evidence gap; largely confirmatory of existing CVOT data |
| Clinical Relevance | 7 | Elderly patients (≥75) are frequently under-represented in trials; confirming consistent CV benefit across age strata has direct prescribing implications |
| Population Reach | 9 | GLP-1 RAs are among the most widely prescribed drug classes globally; diabetes and obesity affect hundreds of millions |
| Implementation Speed | 8 | No new infrastructure needed; findings inform immediate prescribing decisions for elderly patients already being considered for these drugs |
| Evidence Strength | 6 | Meta-analysis of RCTs is a strong design, but only 4 trials reported ≥3 age strata; ≥75 group was small; aggregate data meta-analysis limits granularity |
Key quantitative result: No clear evidence of effect modification by age (65–<75 or ≥75 vs. <65); RHR confidence intervals overlap, but ≥75 data from only 4 trials. External validation: Builds on established CVOT literature (LEADER, SUSTAIN-6, REWIND, HARMONY); incremental rather than transformative. Main limitation: Only 4 trials with 3 age strata; ≥75-year group small; aggregate (not individual patient) data; limited ability to account for frailty, polypharmacy, renal function. Equity implications: Older adults, particularly those ≥75, are a systematically underrepresented population in CVOTs; this meta-analysis partially addresses that gap but cannot fully resolve it. Evidence Maturity (confirmed): Validated
Article 5 — Mashayekhi et al., Walnut Consumption and Inflammatory Markers (PMID: 42947498)
Systematic Review and Dose-Response Meta-Analysis
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Walnut-inflammation literature is mature; dose-response modeling adds a modest methodological layer |
| Clinical Relevance | 4 | Small CRP/IL-6 reductions are biologically plausible but clinical significance is modest; no actionable drug-equivalent effect |
| Population Reach | 7 | General adult population; dietary advice potentially applicable globally |
| Implementation Speed | 8 | Dietary recommendations require no regulatory pathway; could inform nutrition guidelines immediately |
| Evidence Strength | 5 | Meta-analytic design is appropriate; effect sizes described as "small"; no significant effects on TNF-α or adipokines; heterogeneity of included trials likely |
Key quantitative result: Small reductions in CRP and IL-6; no significant effect on TNF-α or adipokines. Main limitation: Small effect sizes; publication bias likely in nutrition RCT literature; dose-response modeling from heterogeneous studies. Equity implications: Walnuts are relatively expensive and inaccessible in lower-income settings; dietary diversity concerns. Evidence Maturity (confirmed): Validated (but effect sizes modest)
Article 6 — Koskiniotis et al., Corticosteroid Injection vs. Night Splints for Carpal Tunnel Syndrome (PMID: 42947526)
Systematic Review and Meta-Analysis of RCTs, n=407
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CSI vs. splinting is a well-studied comparison; sensitivity analysis emphasis on low-bias studies adds methodological value |
| Clinical Relevance | 6 | CTS is extremely common; confirming CSI superiority in symptom and function on highest-quality studies informs clinical decisions |
| Population Reach | 7 | CTS affects ~3–6% of the general adult population; ~1 in 10 working-age adults in high-risk occupations |
| Implementation Speed | 8 | CSI is already widely available; results could shift primary care practice immediately |
| Evidence Strength | 7 | Meta-analysis of RCTs, n=407, sensitivity analysis on low-bias trials specifically; well-designed synthesis |
Key quantitative result: CSI favored symptom improvement (MD −0.56, 95% CI −0.97 to −0.15, p=0.007) and functional status (MD −0.27, 95% CI −0.38 to −0.15, p<0.001). Main limitation: Small overall n=407; duration of follow-up and long-term recurrence not addressed; injection access may vary. Equity implications: CSI requires trained provider and access to clinic; splints are lower-cost and more accessible — this finding should be contextualized by access to care. Evidence Maturity (confirmed): Validated
Article 7 — Ji et al., Glycated Proteomics + ML for CV Risk in Peritoneal Dialysis (PMID: 42947327)
Prospective Multicenter Cohort, n=240
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Glycated proteomics combined with ML for CV risk in peritoneal dialysis patients is a genuinely novel approach |
| Clinical Relevance | 6 | Peritoneal dialysis patients face very high CV mortality; improved risk stratification could change monitoring and preventive therapy use |
| Population Reach | 4 | ~200,000–400,000 patients on peritoneal dialysis globally; relevant but niche |
| Implementation Speed | 3 | Glycated proteomics not routinely available; significant infrastructure needed |
| Evidence Strength | 6 | Prospective multicenter design; n=240 is modest; ROC-AUC not specified in abstract (only stated "higher"); external validation not yet done |
Main limitation: Proteomics platform not widely available; specific AUC values not stated in abstract; n=240 limits generalizability. Equity implications: Benefits a high-need population (end-stage renal disease) who are often underserved in clinical trials; technology access disparities would limit benefit. Evidence Maturity (confirmed): Exploratory
Article 8 — Kim et al., ML Prediction of Sleep Efficiency from Questionnaires (PMID: 42947589)
Observational Study, CatBoost ML for Sleep Metrics
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ML-based sleep prediction from questionnaires is an active area; CatBoost application is incremental |
| Clinical Relevance | 5 | Could reduce polysomnography burden if validated; useful for triaging sleep clinic referrals |
| Population Reach | 6 | Sleep disorders are extremely prevalent (~1 billion globally); but applicability depends on external validation |
| Implementation Speed | 4 | Questionnaire-based model is low-cost but requires validation in diverse clinical settings |
| Evidence Strength | 4 | Observational design; sample size not reported; single-site likely; no external validation stated |
Evidence Maturity (confirmed): Exploratory
Article 9 — Alkoby-Meshulam et al., Prehospital Analgesia in Trauma (PMID: 42947661)
Systematic Review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Prehospital analgesia safety/efficacy is well-established; this is confirmatory synthesis |
| Clinical Relevance | 6 | Favourable safety profile across adult trauma reinforces existing EMS protocols |
| Population Reach | 7 | Trauma is a leading cause of death/disability globally; relevant to all EMS systems |
| Implementation Speed | 7 | Already in practice; this reinforces rather than changes protocols |
| Evidence Strength | 6 | Systematic review of varied study designs; conclusions broadly accepted |
Evidence Maturity (confirmed): Validated
Article 10 — Jiang et al., Sarcopenia, Sleep, and Depression in Chinese Adults (PMID: 42937745)
Prospective Cohort, CHARLS
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Sarcopenia-depression link is known; sleep mediation hypothesis is somewhat novel but not confirmed |
| Clinical Relevance | 5 | Highlights sarcopenia as depression risk factor; but intervention implications remain indirect |
| Population Reach | 6 | Middle-aged/older adults; large population globally; results specific to Chinese cohort |
| Implementation Speed | 4 | Informs screening priorities; implementation depends on further validation |
| Evidence Strength | 5 | Prospective cohort using CHARLS (large, validated dataset); sleep mediation not confirmed after adjustment |
Evidence Maturity (confirmed): Exploratory ⚪
Article 11 — Lertwilaiwittaya, Telomere Biology Disorders Review (PMID: 42944605)
Narrative Review / Clinical Genetics
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Long-read sequencing and chromosome-specific telomere measurement are genuinely emerging; review synthesizes a fast-moving area |
| Clinical Relevance | 5 | Rare disorders; recognition enables potential early intervention; no new treatments described |
| Population Reach | 3 | Ultra-rare disease population; high unmet need but very small numbers |
| Implementation Speed | 3 | Technology adoption in clinical labs is gradual |
| Evidence Strength | 3 | Narrative review; no primary data |
Evidence Maturity (confirmed): Exploratory
Article 12 — Adshead et al., Cost-Effectiveness of CVRM Screening (PMID: 42945057)
Microsimulation Modeling, UK/France/Germany/Australia
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Multi-country CVRM screening cost-effectiveness modeling is useful policy input |
| Clinical Relevance | 6 | Population-level screening optimization has real health system value |
| Population Reach | 8 | Addresses entire cardiovascular-renal-metabolic risk population across 4 high-income countries |
| Implementation Speed | 4 | Policy change requires regulatory and payer adoption |
| Evidence Strength | 4 | Modeling study with deterministic (not probabilistic) sensitivity analysis; significant assumption dependency |
Evidence Maturity (confirmed): Exploratory
Article 13 — Mizdrak et al., Alcohol Harm Interventions Cost Savings NZ (PMID: 42946132)
Modeling Study, New Zealand
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Alcohol policy cost-effectiveness modeling is well-established literature |
| Clinical Relevance | 4 | Health policy relevance; indirect clinical value |
| Population Reach | 5 | New Zealand-specific; broadly applicable frameworks |
| Implementation Speed | 3 | Policy implementation is slow |
| Evidence Strength | 4 | Modeling study; context-specific assumptions |
Evidence Maturity (confirmed): Exploratory
Article 14 — Cunningham et al., ctDNA Surveillance in HR+ HER2- Early Breast Cancer (TRAK-ER) (PMID: 42946309)
Prospective Cohort, ctDNA in Early Breast Cancer
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Prospective ctDNA surveillance with defined molecular relapse rates and radiological correlation in ER+ early breast cancer is novel and practice-informing |
| Clinical Relevance | 7 | Identifying molecular relapse before radiological progression could allow earlier intervention; directly informs implementation of ctDNA monitoring |
| Population Reach | 7 | HR+/HER2- EBC is the most common breast cancer subtype; affects hundreds of thousands annually |
| Implementation Speed | 4 | ctDNA surveillance platforms need standardization and coverage before widespread adoption |
| Evidence Strength | 5 | Prospective design is appropriate; sample size not reported; abstract-only; no demonstrated survival benefit yet from surveillance |
Evidence Maturity (confirmed): Exploratory 🔴
Article 15 — Tsirelman et al., Danon Disease Clinical Review (PMID: 42946694)
Narrative Review, Danon Disease Gene Therapy
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Summarizes Phase 1 AAV9-LAMP2B gene therapy and clinical phenotypes |
| Clinical Relevance | 5 | Very rare; heart transplant is current standard; gene therapy proof-of-concept is meaningful |
| Population Reach | 2 | Ultra-rare; estimated <1/100,000 |
| Implementation Speed | 2 | Phase 1 only; years from clinical use |
| Evidence Strength | 3 | Narrative review; primary data cited are Phase 1 |
Evidence Maturity (confirmed): Exploratory ⚪
Article 16 — Vu et al., Arthroplasty After Hemophilia Gene Therapy (PMID: 42947409)
Narrative Review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Perioperative management of post-gene-therapy hemophilia patients is a new and practical clinical question |
| Clinical Relevance | 6 | Hemophilia patients receiving gene therapy are a growing population needing surgical guidance |
| Population Reach | 3 | Hemophilia affects ~400,000 globally; gene-therapy-treated subset is still small |
| Implementation Speed | 5 | Guidance can be adopted by hemophilia treatment centers immediately |
| Evidence Strength | 3 | Narrative review; limited primary data |
Evidence Maturity (confirmed): Exploratory
Article 17 — Jinyi et al., AI Handheld Ultrasound Stroke Risk Decision System (PMID: 42947532)
Prospective Cohort, n=140, Carotid Plaque + AI
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AI-powered handheld ultrasound for stroke risk stratification in resource-limited settings is an innovative implementation |
| Clinical Relevance | 6 | Stroke prevention via early risk stratification has high value; handheld format addresses access gap |
| Population Reach | 7 | Stroke is a leading global cause of death/disability; carotid plaque prevalence is high in aging populations |
| Implementation Speed | 4 | Point-of-care format enables faster adoption in LMICs; regulatory approval needed |
| Evidence Strength | 5 | Prospective cohort; n=140 is small; clinical validation reported but limited scope |
Evidence Maturity (confirmed): Exploratory 🟡
Article 18 — Rajendran et al., ESR1 Mutations and Endocrine Resistance Review (PMID: 42937403)
Narrative Review, ER+ Breast Cancer
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Synthesizes established literature on ESR1 mutations and emerging oral SERDs; limited new content |
| Clinical Relevance | 6 | Elacestrant is approved; review informs clinical context around liquid biopsy and SERD selection |
| Population Reach | 7 | HR+/HER2- metastatic breast cancer is a large population |
| Implementation Speed | 6 | Elacestrant already FDA-approved; liquid biopsy for ESR1 monitoring is increasingly available |
| Evidence Strength | 3 | Narrative review only |
Evidence Maturity (confirmed): Exploratory
Article 19 — Ghorani et al., Pembrolizumab for Drug-Resistant GTN (PMID: 42937425)
Retrospective Multicenter Cohort, n=60, NEJM Evidence
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Pembrolizumab in drug-resistant GTN with HLA-G biomarker exploration is novel; GTN is a chemosensitive cancer and this represents a salvage pathway |
| Clinical Relevance | 7 | Drug-resistant GTN has very limited salvage options; immunotherapy signals in this context are clinically important |
| Population Reach | 3 | GTN is rare (~1/1,000–40,000 pregnancies); but affects young women with high life-years at stake |
| Implementation Speed | 3 | Retrospective; needs prospective validation before standard use |
| Evidence Strength | 5 | Multicenter international design is a strength; retrospective limits causal inference; n=60; published in NEJM Evidence |
Equity implications: Predominantly affects women of reproductive age; incidence higher in some Asian countries; access to pembrolizumab is a major global equity concern. Evidence Maturity (confirmed): Exploratory 🟠
Article 20 — Magouliotis et al., Liquid Biopsy for Oligometastatic NSCLC (PMID: 42938871)
Narrative Review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Nuanced review separating established from hypothetical ctDNA evidence in NSCLC surgery decisions |
| Clinical Relevance | 5 | Framework is useful but largely summarizes existing knowledge gaps |
| Population Reach | 7 | NSCLC is among the most common cancers globally |
| Implementation Speed | 3 | Defines what trials are needed; not yet practice-changing |
| Evidence Strength | 3 | Narrative review |
Evidence Maturity (confirmed): Exploratory
Article 21 — Caringi et al., Liquid Biopsy in HPB Malignancies (PMID: 42938881)
Narrative Review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Sobering review noting lack of clinical benefit from ctDNA-guided modifications in HPB cancers |
| Clinical Relevance | 5 | Negative finding is informative; prevents premature adoption |
| Population Reach | 6 | Pancreatic/hepatobiliary cancers are high-mortality malignancies |
| Implementation Speed | 3 | Identifies gaps; no ready implementation |
| Evidence Strength | 3 | Narrative review |
Evidence Maturity (confirmed): Exploratory
Article 22 — Bui et al., FragMIL cfDNA Cancer Detection (PMID: 42938921)
ML Framework for Early Cancer Detection, Multiple Cohorts
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Fragment-token multiple-instance learning applied to cfDNA fragmentomics is a methodologically novel approach |
| Clinical Relevance | 5 | Validated on existing cohorts; not yet a clinical tool; AUROCs are high but external prospective validation needed |
| Population Reach | 8 | Multi-cancer early detection has enormous population-scale potential |
| Implementation Speed | 3 | Requires prospective clinical validation and regulatory pathway |
| Evidence Strength | 5 | Validated on 3 independent cohorts (DELFI, LUCAS, Jiang); retrospective; performance varies by cohort (0.802–0.963) |
Key quantitative result: AUROC 0.963 (DELFI), 0.802 (LUCAS), 0.910 (Jiang). Evidence Maturity (confirmed): Exploratory 🔴
Article 23 — Basancelebi et al., ML Classification of Thalassemia from CBC (PMID: 42938973)
ML Study, CBC-Based Hemoglobin E/Thalassemia Classification
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ML thalassemia classification from CBC is an active niche; synthetic oversampling analysis adds methodological insight |
| Clinical Relevance | 4 | Potentially useful in high-prevalence regions; but clinical validation and head-to-head with standard screening not shown |
| Population Reach | 5 | Thalassemia is prevalent in South/Southeast Asia, Middle East, Mediterranean |
| Implementation Speed | 4 | CBC is universally available; model deployment needs validation |
| Evidence Strength | 4 | Single study; sample size not reported; mixed oversampling results |
Evidence Maturity (confirmed): Exploratory
Article 24 — Yang et al., Breast Cancer Stem Cell Extracellular Vesicles (PMID: 42939051)
Narrative Review, BCSC-EV Biomarkers
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Source-resolved isolation of cancer stem cell EVs as distinct liquid biopsy signals is a forward-looking concept |
| Clinical Relevance | 4 | Purely conceptual at this stage; no clinical validation data |
| Population Reach | 7 | Breast cancer is the most common cancer in women globally |
| Implementation Speed | 2 | Years from clinical utility |
| Evidence Strength | 3 | Narrative review |
Evidence Maturity (confirmed): Exploratory
Articles 25–45 (Rapid Scoring Summary)
| # | PMID | Title (short) | Novelty | Clinical Rel. | Pop. Reach | Impl. Speed | Evid. Strength | Evidence Maturity |
|---|---|---|---|---|---|---|---|---|
| 25 | 42944519 | Seat Height & Shoe Donning in Elderly | 2 | 2 | 3 | 4 | 4 | Exploratory |
| 26 | 42944855 | IFN-I Autoantibodies Plateau in Centenarians | 6 | 3 | 4 | 2 | 5 | Exploratory |
| 27 | 42945122 | Telemonitoring Adoption in Older Adults | 3 | 3 | 5 | 4 | 4 | Exploratory |
| 28 | 42946066 | TP53 Y220C in Ovarian Carcinoma | 4 | 4 | 5 | 3 | 5 | Exploratory |
| 29 | 42946127 | Semaglutide & Panic Attacks Pharmacovigilance | 5 | 6 | 8 | 6 | 5 | Exploratory |
| 30 | 42946155 | Incretin/GPCR Drug Delivery Review | 4 | 4 | 6 | 3 | 3 | Exploratory |
| 31 | 42946163 | SGLT2 Inhibitors & UTI Risk (Nationwide Cohort) | 5 | 7 | 8 | 6 | 6 | Exploratory |
| 32 | 42946406 | PPI Use & Febrile Neutropenia in NHL (R-CHOP) | 5 | 6 | 5 | 5 | 5 | Exploratory |
| 33 | 42946491 | Pan-uveitis as First Presentation of Hodgkin Lymphoma | 4 | 4 | 3 | 3 | 2 | Exploratory |
| 34 | 42946672 | Au-Pd Nanodumbbells Photothermal-Immunotherapy | 5 | 2 | 4 | 1 | 2 | Exploratory |
| 35 | 42946894 | ALK+ Large B-Cell Lymphoma Novel CEP128::ALK | 5 | 3 | 2 | 2 | 2 | Exploratory |
| 36 | 42946946 | GLP-1/Tirzepatide & Diabetic Retinal Outcomes | 5 | 6 | 8 | 5 | 4 | Exploratory |
| 37 | 42946972 | GLP-1 in Type 1 Diabetes Review | 4 | 6 | 6 | 5 | 3 | Exploratory |
| 38 | 42947249 | DLBCL in RA Autoreactive BCRs | 5 | 3 | 4 | 2 | 4 | Exploratory |
| 39 | 42947288 | Monoclonal Protein & Marginal Zone Lymphoma PFS | 5 | 5 | 4 | 3 | 5 | Exploratory |
| 40 | 42947393 | General Anaesthesia Outcomes in Elderly (Nationwide) | 4 | 6 | 7 | 5 | 6 | Exploratory |
| 41 | 42947412 | Genome vs. Exome Sequencing in FFPE Tumors | 6 | 6 | 6 | 4 | 5 | Exploratory |
| 42 | 42947480 | Obesity Indices for Metabolic Syndrome in Taiwanese | 4 | 5 | 5 | 5 | 4 | Exploratory |
| 43 | 42947537 | ML Remote Monitoring for Advanced Parkinson's HTA | 5 | 5 | 5 | 3 | 4 | Exploratory |
| 44 | 42947565 | Chronic Low Back Pain Patient Experiences Model | 3 | 4 | 7 | 4 | 3 | Exploratory |
| 45 | 42946582 | HipSAFE: Hip Fracture Detection via Deep Learning (Porcine) | 5 | 2 | 4 | 2 | 3 | Exploratory |